A new anti-cancer drug in the market: Good news for investors or for patients?

European Journal of Cancer

Volumn 44, Issue 13, 2008, Pages 1786-1788

  Apolone, Giovanni ^a   Tafuri, Giovanni ^b,c   Trotta, Francesco ^b   Garattini, Silvio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b ITALIAN MEDICINES AGENCY   (Italy)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; ECONOMIC ASPECT; ETHICS; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE; HUMAN; POLICY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; REIMBURSEMENT; RISK BENEFIT ANALYSIS;

EID: 49549095319     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.021     Document Type: Note

References (13)

1. Garattini S., and Bertelè V. Efficacy, safety and cost of new anticancer drugs. BMJ 325 (2002) 269-271
2. Johnson J.R., Williams G., and Pazdur R. Endpoints and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21 (2003) 1404-1411
3. Dagher R., Johnson J., Williams G., Keegan P., and Pazdur R. Accelerated approval of oncology products. A decade of experience. J Natl Cancer Inst 96 (2004) 1500-1509
4. Apolone G., Joppi R., and Bertelè V & S. Ten years of marketing approvals of anti-cancer drugs in Europe. Regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer 93 (2005) 504-509
5. Bertele' V., Banzi R., Capasso F., et al. Haematological anticancer drugs in Europe: Any added value at the time of approval?. Eur J Clin Pharm 63 (2007) 713-719
6. Carpenter D., Zucker E.J., and Avorn J. Drug-review and safety problems. N Engl J Med (2008) 358-1354-1361
7. Montori V.M., Devereaux P.J., Adhikari N.K., et al. Randomized trials stopped early for benefit: a systematic review. JAMA 294 (2005) 2203-2209
8. Bassler D., Montori V.M., Briel M., Glasziou P., and Guyatt G. Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol. 61 (2008) 241-246
9. Segota E., Soares H.P., Djulbegovic B., et al. Randomized clinical trials in oncology stopped early for benefits (RCTSEB). J Clin Oncol 24 (2006) abstr 6039
10. Wilcox R.A., Djulbegovic B., Moffitt H.L., Guyatt G.H., and Montori V.M. Randomized trials in oncology stopped early for benefit. J Clin Oncol. 26 (2008) 18-19
11. Trotta F., Apolone G., Garattini S., and Tafuri G. Stopping a trial early in oncology: for patients or for industry. Ann Oncol 19 (2008) 1347-1353
12. Aronson J.K. Something new every day: defining innovation and innovativeness in drug therapy. J Amb Manage Care. 31 (2008) 65-68
13. Apolone G., and Patarnello F. Finance fibrillation and research rhythm: do we need a pace-maker?. J Amb Care Manage 31 (2008) 183-185